



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/865,195	05/24/2001	William L. Hunter	110129.420C2	3009

500 7590 03/09/2004

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC  
701 FIFTH AVE  
SUITE 6300  
SEATTLE, WA 98104-7092

EXAMINER
----------

SZMAL, BRIAN SCOTT

ART UNIT	PAPER NUMBER
----------	--------------

3736

DATE MAILED: 03/09/2004

16

Please find below and/or attached an Office communication concerning this application or proceeding.

SR

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/865,195	HUNTER ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Brian Szmaj	3736	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 08 January 2004.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) See Continuation Sheet is/are pending in the application.
- 4a) Of the above claim(s) See Continuation Sheet is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,5,8,9,11,12,15,18-20,57,66-77,182,201,207,208,220-222,230,358-365,373 and 374 is/are rejected.
- 7) ☒ Claim(s) 13,14 and 78-82 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

***Claim Rejections - 35 USC § 103***

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 1, 5, 8, 12, 15, 18-20, 57, 66-77, 182, 201, 207, 208, 220-222, 230, 358-365, 373 and 374 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slater et al in view of Brem et al ('986).

Slater et al disclose radioactive therapeutic seeds and spacers for separating the seeds and further disclose; the radioactive source is selected from I-125, Pd-103, Ir-192, Co-60, Cs-137 and Ru-106; the radioactive source comprises a plurality of seeds; the radioactive source is positioned into tissue of a patient adjacent to a site to be treated by radiation; the radiation prevents cellular proliferation; the cellular proliferation is due to cancer; the radioactive source is administered within a body cavity; the radioactive source is administered directly into a body tissue; the disease of the prostate is prostate cancer; the spacer is positioned between adjacent seeds, the spacers holding the adjacent seeds apart and holding the plurality of seeds together as part of a continuous thread; and the seeds and spacers are sized to be received in a catheter for insertion into the tissue. See Column 1, lines 15-22 and 54-58; and Column 7, lines 35-54. Even though Slater et al disclose a bioabsorbable spacer for use with the radioactive seeds, Slater et al fails to disclose a polymer with a cell-cycle inhibitor; the polymer

Art Unit: 3736

comprises poly(lactic acid); the cell-cycle inhibitor is an alkylating agent; and the cell-cycle inhibitor comprises paclitaxel.

Brem et al disclose controlled local delivery of chemotherapeutic agents for treating solid tumors and further disclose a polymer with a cell-cycle inhibitor; the polymer comprises poly(lactic acid); the cell-cycle inhibitor is an alkylating agent; and the cell-cycle inhibitor comprises paclitaxel. See Column 5, lines 25-49; and Column 7, lines 32-49.

Since both Slater et al and Brem et al disclose means for treating tumors, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the system and method of Slater et al to include the use of a biodegradable polymer with a cell-cycle inhibitor, as per the teachings of Brem et al, since it would provide a spacer that has a means of providing localized chemotherapy along with localized radiation from the seed at a tumor site.

3. Claims 9, 11 and 83 are rejected under 35 U.S.C. 103(a) as being unpatentable over Slater et al and Brem et al ('986) as applied to claims 1 and 19 above, and further in view of Mavity et al ('057).

Slater et al and Brem et al, as discussed above, disclose means for providing localized radiation and chemotherapy to a tumor site, but fail to disclose the radiation is released from the polymer; the polymer is a biodegradable polymer; and the use of a cell-cycle inhibitor carried by the outer member on the radioactive seed.

Mavity et al disclose absorbable brachytherapy and chemotherapeutic delivery devices and methods and further disclose the radiation is released from the polymer; the

Art Unit: 3736

polymer is a biodegradable polymer; and a cell-cycle inhibitor carried by the outer member on the radioactive seed. See Column 12, lines 31-33 and 46-48.

Since Slater et al, Brem et al and Mavity et al disclose means for delivering localized radiation and chemotherapeutic substances to a tumor site, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device and method of Slater et al and Brem et al to include the use of a coating on the radioactive seed for delivering the cell-cycle inhibitor, as per the teachings of Mavity et al, since it would provide a means of delivering radiation and a chemotherapeutic agent to the exact same spot utilizing a single implant rather than have a chemotherapeutic agent adjacent a radioactive seed.

#### ***Allowable Subject Matter***

4. Claims 13, 14 and 78-82 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### ***Response to Arguments***

5. Applicant's arguments filed January 8, 2004 have been fully considered but they are not persuasive. The Examiner respectfully traverses regarding the Applicant's argument that the disclosure of Slater et al does not enable the use of a bioabsorbable spacer because the bioabsorbable material was not explicitly disclosed. Even though the disclosure of a bioabsorbable spacer in Slater et al is broad, and does not explicitly

Art Unit: 3736

disclose at least one specific polymer, it would have been obvious to one of ordinary skill in the art to recognize the disclosure of a bioabsorbable spacer includes spacers that are made out of bioabsorbable polymers such as those disclosed in Brem et al because it was well known in the art that specific polymers are used for bioabsorbable devices. Therefore the disclosure of Slater et al does enable the use of a bioabsorbable spacer even though no specific polymer was disclosed.

Furthermore, the argument that one of ordinary skill in the art would not have a reasonable expectation of success by combining Slater et al and Brem et al, is respectfully traversed by the Examiner. There is no suggestion in the disclosure of Brem et al that small spacers could not be made from the disclosed polymers. Specifically, Brem et al discloses the creation of a 2.5 mm implant utilizing a mold (See Column 14, lines 54-58). Since the disclosed polymers of Brem et al can be molded into at least one shape for an implant, it would have been reasonable that one of ordinary skill in the art would be able to create a brachytherapy seed spacer utilizing the same polymers with chemotherapeutic drugs dispersed within the polymeric matrix with a degree of success.

6. In response to applicant's argument that it would have not been obvious to one of ordinary skill in the art to combine the references of Slater et al and Brem et al to achieve a radioactive seed and therapeutic bioabsorbable spacer, the test for obviousness is not whether the features of a secondary reference may be bodily incorporated into the structure of the primary reference; nor is it that the claimed invention must be expressly suggested in any one or all of the references. Rather, the

Art Unit: 3736

test is what the combined teachings of the references would have suggested to those of ordinary skill in the art. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981).

7. In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, the invention of Brem et al was issued on June 29, 1997, disclosing the use of biodegradable polymers with chemotherapeutic drugs incorporated within the matrix to produce bioabsorbable chemotherapeutic products, and Slater et al, issued on June 27, 2000, discloses the use of biodegradable spacers coupling radioactive seeds. Therefore, one of ordinary skill in the art at the time of the invention of Slater et al would have been able to utilize the polymer matrix with the chemotherapeutic drugs disclosed by Brem et al to create the currently claimed spacer, and therefore create the currently claimed invention.

### ***Conclusion***

8. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 3736

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Szmal whose telephone number is (703) 308-3737. The examiner can normally be reached on Monday-Friday, with second Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mary Beth Jones can be reached on (703) 308-3400. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.



Art Unit: 3736

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

BS

*BS*

*Mary Beth Jones*  
*Acting SPE*  
*AV 3736*

Continuation of Disposition of Claims: Claims pending in the application are 1-6,8,9,11-57,66-83,134182,201-208,220-222,230-232,239-242,247-253,255-258,262-266,271,273-275,278-281,286,288-291,294,298,300-303,309,311-313,321-323,328,330,331,336,338-341,346-348,353-375.

Continuation of Disposition of Claims: Claims withdrawn from consideration are 2-4,6,13,14,16,17,21-56,134-181,202-206,231,232,239-242,247-253,255-258,262-266,271,273-275,278-281,288-291,294,298,300-303,309,311-313,321,323,328,330,331,336,338-341,346-348,353-357,367-372 and 375.